SCHEMBL26032028

SCHEMBL26032028

CCCCCCCCCCCCCCCCCC(=O)NCCOCCNC(=O)CCOCCNC(=O)CCOCCOCCOCCOCCN(CCOCCOCCOCCOCCC(=O)NCCOCCC(=O)NCCOCCNC(=O)CCCCCCCCCCCCCCCCC)C(=O)CCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
DRD2 P14416 1/20 0.34
DNM1 Q05193 2/20 0.34
GLP1R P43220 8/20 0.34
F2 P00734 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26032030 1.00 HPGD (0.40) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032063 0.93 HPGD (0.34) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032226 0.91 HPGD (0.43) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL13814445 0.85 HPGD (0.48) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032070 0.83 GLP1R (0.52) HPGDHTTSMN1; SMN2GLP1RLPAR1
SCHEMBL26032035 0.83 GLP1R (0.52) HPGDHTTSMN1; SMN2GLP1RLPAR1
SCHEMBL26032037 0.83 GLP1R (0.52) HPGDHTTSMN1; SMN2GLP1RLPAR1
SCHEMBL14750406 0.82 SMN1; SMN2 (0.39) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032098 0.82 CNR1 (0.39) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032095 0.82 CNR1 (0.39) HPGDHTTSMN1; SMN2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 HPGD 3988/4885HTT 4208/4885SMN1; SMN2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.